CYTOSORBENTS CORPORATION
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M | $41.0M | $24.9M | $22.5M |
| Cost of Revenue | $10.6M | $10.7M | $9.1M | $14.0M | $11.0M | $11.1M | $7.4M | $7.5M |
| Gross Profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M | $30.0M | $17.6M | $15.0M |
| Gross Margin | 71.5% | 69.9% | 70.6% | 59.8% | 74.4% | 73.0% | 70.5% | 66.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | $15.7M | $15.1M | $16.4M | $8.8M | $12.1M | $7.7M |
| SG&A Expense | $35.6M | $33.7M | $38.3M | $34.3M | $35.8M | $28.5M | $22.0M | $20.9M |
| Operating Income | $-14.7M | $-16.5M | $-31.9M | $-31.5M | $-22.7M | $-10.4M | $-19.0M | $-15.6M |
| Operating Margin | -39.8% | -46.2% | -102.8% | -90.9% | -52.7% | -25.3% | -76.0% | -69.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-8.6M | $-22.4M | $-30.1M | $-33.9M | $-25.3M | $-9.0M | $-20.4M | $-17.8M |
| Income Tax Expense | $-401.0K | $-1.7M | $-813.7K | $-1.1M | $-736.0K | $-1.1M | $-1.1M | $-619.5K |
| Net Income | $-8.2M | $-20.7M | $-29.2M | $-32.8M | $-24.6M | $-7.8M | $-19.3M | $-17.2M |
| Net Margin | -22.1% | -58.2% | -94.1% | -94.6% | -56.9% | -19.1% | -77.2% | -76.5% |
| EPS (Basic) | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 | $-0.20 | $-0.60 | $-0.56 |
| EPS (Diluted) | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 | $-0.20 | $-0.60 | $-0.56 |
| Shares Outstanding (Basic) | 62.2M | 54.4M | 44.7M | 43.6M | 43.4M | 38.8M | 32.3M | 31.8M |
| Shares Outstanding (Diluted) | 62.2M | 54.4M | 44.7M | 43.6M | 43.4M | 38.8M | 32.3M | 31.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |